Satralizumab, previously known as the SA-237 molecule, represents a significant therapy for neuromyelitis optica spectrum disorder and other autoimmune ailments. Recent clinical trials have shown encouraging data regarding its efficacy in preventing relapses and disease progression . Notably, Phase III trials – including the ADAPT study – have

New data suggests that Cilgavimab, formerly known as COV2-2130, holds significant capability as a clinical agent against COVID-19. This protein exhibits a unique method of function, particularly neutralizing the pathogen's ACE2-RBD with considerable strength . Early studies indicate a strong capacity to block infection , possibly offering a valuabl